Member Info for lloydyboy

You sold out for that post- you shouldn’t have bothered buying in the first place

Interesting. I found different earlier that is all

But on the other hand- this shows they held in 2019 and no further source of info https://live.euronext.com/en/product/equities/FR0010397232-ALXP/company-information

They held it in 2017. Novacyt has no significant holders over 3%

some of the **** posted here is truly unbelievable.

that a lot wanted the dPCR this month and it will roll into next month, out of the companies hands. That is the transformational news. Increase in projected output from 8 to 10mil is fantastic news. Let the company get on with what they are doing. Anything else here apart from research is white noise.

what news do you want?

90million turnover- that’s half the Mcap now give or take- mental

Agreed gggg avct is a non starter. Novacyt is in a better position today than what we knew about yesterday. Good to go.

when is that then?

France looks **** like it does every other day.

Matt Han**** set this in the press briefing last Friday. What is the benefit of antibody testing out of interest?

Fraud then. Idiot

Get back to sng and make a with some of the wool from that post

dirt cheap at the minute. Wish i have more funds..... ffs

Undoubtedly there will be a second spike. South Korea and Germany, two countries that handled the situation better than us in the first instance are noticing rising cases after lockdown easements. In all honesty we don’t have a chance. 47 days into lockdown and we still don’t know our arse from our elbow as a country...

Morning , the issue surrounding the french market is their legislation is written for a less accurate test. It is not saying that novacyt has the wrong test, a bad test. It is down to the specificity of our test. It is not being blocked but the question in hand is that novacyt test is too specific to be claimed back on insurance- directly linking to the 700,000 tests discussion that came out the county in interview last week. It would be nice to be the default provider over there though as the CAC drives the share price over here and the french investors need more Molly coddling and peace of mind than aim investors over here. Watch this space

It actually sums up the level of consideration and foresight that you put into your post, research and trading abilities. You talk about going back to your old faithful shares, so you have no vindication in your initial investment in the first instance. The company is holding well against its peers and is in a trading range, this is because it is listed across two indices and is cash flow positive since the covid 19 saga, two thirds of the aim covid related stocks are hype. Not making money, chasing the antibody dream which with track and trace does not fit in to the plan. It does not matter what competitors are doing. It does not matter who France use for their tests. Novacyt are working to capacity and it is generating a good income. This will improve the balance sheet. The real news is in new oem agreements, the production levels coming out of the USA to service their market and potentially the Indonesian and Asian markets. But the real big one is the amount of time the d-pcr shaves off the production time, the amount of money it saves on the reagents and the cost. This will lift production output. We are at capacity and to get over the 300mil Mcap you will want to see greater production on better margins with longevity of agreements. With the WHO, FDA and EUA’s servicing in excess of 100 countries, the production levels stay the same. So in summary, yes your post is boring. I am also happy with my holding from 69p cheers. Good luck with your old faithfuls. I would also love to see a Middle East or Indian OEM to get production levels in excess of 12/15 mil. Then you are in a different league in regards of Mcap. Night night

Boring

Sales and expansion are pretty good drivers too